Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis

Elizabeth M. Cameron; Sade Spencer; Jonathan Lazarini; Christopher T. Harp; E. Sally Ward; Mark Burgoon; Gregory P. Owens; Michael K. Racke; Jeffrey L. Bennett; Elliot M. Frohman; Nancy L. Monson

doi:10.1016/j.jneuroim.2009.05.014

Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis

Elizabeth M. Cameron, Sade Spencer, Jonathan Lazarini, Christopher T. Harp, E. Sally Ward, Mark Burgoon, Gregory P. Owens, Michael K. Racke, Jeffrey L. Bennett, Elliot M. Frohman, Nancy L. Monson

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

We identified a unique antibody gene mutation pattern (i.e. "signature") in cerebrospinal fluid (CSF) B cells from multiple sclerosis (MS) patients not present in control populations. Prevalence of the signature in CSF B cells of patients at risk to develop MS predicted conversion to MS with 91% accuracy in a small cohort of clinically isolated syndrome patients. If confirmed, signature prevalence would be a novel genetic diagnostic tool candidate for patients with early demyelinating disease of the central nervous system.

Original language	English (US)
Pages (from-to)	123-130
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	213
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2009.05.014
State	Published - Aug 18 2009
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported by grants from the National Institutes of Health (NIH) to NLM (RO1 NS 40993) and MKR (RO1 NS 37513, RO1 AI 47133, and K24 NS 44250), the National Multiple Sclerosis Society (NMSS) to NLM (RG3267) and JLB (RG3908), the Yellow Rose Foundation (NLM and MKR), the Wadsworth Foundation (to NLM) and Howson funds (to NLM). EMC and CH were supported by NIH NRSA5 T32 AI 005284-28 from NIAID. The authors have no conflicting financial interests.

Keywords

Antibodies
B lymphocytes
Gene rearrangement
Multiple sclerosis
Mutational signature

Publisher link

10.1016/j.jneuroim.2009.05.014

Find It

Find It at U of M Libraries

Cite this

Cameron, E. M., Spencer, S., Lazarini, J., Harp, C. T., Ward, E. S., Burgoon, M., Owens, G. P., Racke, M. K., Bennett, J. L., Frohman, E. M., & Monson, N. L. (2009). Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. Journal of Neuroimmunology, 213(1-2), 123-130. https://doi.org/10.1016/j.jneuroim.2009.05.014

@article{7eeca7c136db4c82aba5cd822e639aa8,

title = "Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis",

abstract = "We identified a unique antibody gene mutation pattern (i.e. {"}signature{"}) in cerebrospinal fluid (CSF) B cells from multiple sclerosis (MS) patients not present in control populations. Prevalence of the signature in CSF B cells of patients at risk to develop MS predicted conversion to MS with 91% accuracy in a small cohort of clinically isolated syndrome patients. If confirmed, signature prevalence would be a novel genetic diagnostic tool candidate for patients with early demyelinating disease of the central nervous system.",

keywords = "Antibodies, B lymphocytes, Gene rearrangement, Multiple sclerosis, Mutational signature",

author = "Cameron, {Elizabeth M.} and Sade Spencer and Jonathan Lazarini and Harp, {Christopher T.} and Ward, {E. Sally} and Mark Burgoon and Owens, {Gregory P.} and Racke, {Michael K.} and Bennett, {Jeffrey L.} and Frohman, {Elliot M.} and Monson, {Nancy L.}",

note = "Funding Information: This study was supported by grants from the National Institutes of Health (NIH) to NLM (RO1 NS 40993) and MKR (RO1 NS 37513, RO1 AI 47133, and K24 NS 44250), the National Multiple Sclerosis Society (NMSS) to NLM (RG3267) and JLB (RG3908), the Yellow Rose Foundation (NLM and MKR), the Wadsworth Foundation (to NLM) and Howson funds (to NLM). EMC and CH were supported by NIH NRSA5 T32 AI 005284-28 from NIAID. The authors have no conflicting financial interests. ",

year = "2009",

month = aug,

day = "18",

doi = "10.1016/j.jneuroim.2009.05.014",

language = "English (US)",

volume = "213",

pages = "123--130",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis

AU - Cameron, Elizabeth M.

AU - Spencer, Sade

AU - Lazarini, Jonathan

AU - Harp, Christopher T.

AU - Ward, E. Sally

AU - Burgoon, Mark

AU - Owens, Gregory P.

AU - Racke, Michael K.

AU - Bennett, Jeffrey L.

AU - Frohman, Elliot M.

AU - Monson, Nancy L.

N1 - Funding Information: This study was supported by grants from the National Institutes of Health (NIH) to NLM (RO1 NS 40993) and MKR (RO1 NS 37513, RO1 AI 47133, and K24 NS 44250), the National Multiple Sclerosis Society (NMSS) to NLM (RG3267) and JLB (RG3908), the Yellow Rose Foundation (NLM and MKR), the Wadsworth Foundation (to NLM) and Howson funds (to NLM). EMC and CH were supported by NIH NRSA5 T32 AI 005284-28 from NIAID. The authors have no conflicting financial interests.

PY - 2009/8/18

Y1 - 2009/8/18

N2 - We identified a unique antibody gene mutation pattern (i.e. "signature") in cerebrospinal fluid (CSF) B cells from multiple sclerosis (MS) patients not present in control populations. Prevalence of the signature in CSF B cells of patients at risk to develop MS predicted conversion to MS with 91% accuracy in a small cohort of clinically isolated syndrome patients. If confirmed, signature prevalence would be a novel genetic diagnostic tool candidate for patients with early demyelinating disease of the central nervous system.

AB - We identified a unique antibody gene mutation pattern (i.e. "signature") in cerebrospinal fluid (CSF) B cells from multiple sclerosis (MS) patients not present in control populations. Prevalence of the signature in CSF B cells of patients at risk to develop MS predicted conversion to MS with 91% accuracy in a small cohort of clinically isolated syndrome patients. If confirmed, signature prevalence would be a novel genetic diagnostic tool candidate for patients with early demyelinating disease of the central nervous system.

KW - Antibodies

KW - B lymphocytes

KW - Gene rearrangement

KW - Multiple sclerosis

KW - Mutational signature

UR - http://www.scopus.com/inward/record.url?scp=68049083540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049083540&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2009.05.014

DO - 10.1016/j.jneuroim.2009.05.014

M3 - Article

C2 - 19631394

AN - SCOPUS:68049083540

SN - 0165-5728

VL - 213

SP - 123

EP - 130

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this